C&EN White Paper
Accelerating pharmaceuticals’ time to market: Applications of capsule low-dosing technology
Brought to you by Aenova

Trends in the global R&D pipeline suggest that the pharmaceutical industry is navigating a landscape of competing factors. Though new pharmaceuticals are moving to market faster than ever, developers need time to optimize formulation for the sensitive, high-potency active ingredients that dominate the current pipeline of drug candidates.

The challenge of balancing speed and thorough development can be solved by choosing hard-shell capsules as a dosage form. Manufacturers can dose small amounts of pure active pharmaceutical ingredients (APIs) or simple blends directly into hard capsules. Learn how micro doses less than 5 mg or low doses, which can range from 5 mg to 100 mg, delivered in hard capsules are an accessible solution that enables manufacturers to bring new medicines from R&D to market more quickly.

Key Objectives:
  • Advantages of low-dose capsules over low-dose tablets
  • Advances in precision powder filling that ensure 100% control of each capsule’s content
  • How low-dose capsules can speed many stages of pharmaceutical development

Brought to you by:
Please complete the form to download the white paper.
*By submitting this form, you agree to receive more information on related products and services from the American Chemical Society (ACS Publications) and its sponsor via email. ACS takes your privacy seriously. For more information, please see the ACS Privacy Policy.

Copyright © 2023 American Chemical Society | 1155 Sixteenth Street NW | Washington, DC 20036 | View our Privacy Policy